Latest Expert Opinions

Signal
Opinion
Expert
BUY WEAKNESS
BUY WEAKNESS
May 17, 2004
Likes their technology. Good management stability. Have key brand name clients that are starting to sign up. Could drop another 20/30%.
Bioscript (BYT-T)
May 17, 2004
Likes their technology. Good management stability. Have key brand name clients that are starting to sign up. Could drop another 20/30%.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$2.120
Owned
Yes
SELL
SELL
May 17, 2004
Can't stand how they have executed. Rumors of a financial restructuring are hitting the stock. Just raised $40 million.
SR Telecom (SRX-T)
May 17, 2004
Can't stand how they have executed. Rumors of a financial restructuring are hitting the stock. Just raised $40 million.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$3.950
Owned
No
BUY
BUY
May 17, 2004
Have sold a lot of businesses and the remaining one is pretty well tied to the economy. New management has turned it around nicely.
Have sold a lot of businesses and the remaining one is pretty well tied to the economy. New management has turned it around nicely.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$1.220
Owned
No
BUY
BUY
May 17, 2004
Just reported and their earnings were fine but the stock didn't do much. Great balance sheet with $2 a share in cash. Just a matter of time. Good risk return.
Just reported and their earnings were fine but the stock didn't do much. Great balance sheet with $2 a share in cash. Just a matter of time. Good risk return.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$11.300
Owned
Yes
BUY
BUY
May 17, 2004
Just signed a big 10 year contract in the Middle East. Seems to be paid a dividend each quarter.
Just signed a big 10 year contract in the Middle East. Seems to be paid a dividend each quarter.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$4.250
Owned
Yes
WAIT
WAIT
May 17, 2004
Likes some of their businesses, but not others because of competition. Would look at it at a lower price.
Likes some of their businesses, but not others because of competition. Would look at it at a lower price.
Norman Levine
Managing Director, Portfolio Management Corp
Price
$43.750
Owned
No
HOLD
HOLD
May 17, 2004
Johnson and Johnson have come back as a competitive threat on their stents. Long-term will be good. Multiple may be a bit rich.
Johnson and Johnson have come back as a competitive threat on their stents. Long-term will be good. Multiple may be a bit rich.
Norman Levine
Managing Director, Portfolio Management Corp
Price
$25.900
Owned
No